Medicines

Here you will find all of our recommendations listed within a sortable table with a search facility.

Medicine Recommendations

MedicineBrandIndicationDisease CategoryDate Considered by LMMG
AbataceptOrencia®
LMMG RA Biologic Pathway (Subcutaneous monotherapy in patients unable to take methotrexate, as a 3rd line biologic treatment)Musculoskeletal and joint diseasesupdated February 2016
AbataceptOrencia®LMMG RA Biologic Pathway (with Methotrexate where patient has moved through pathway to 3rd line and tocilizumab is contraindicated, withdrawn due to adverse effect, or has been used earlier in treatment pathway)
Musculoskeletal and joint diseases
updated February 2016
AbataceptOrencia ®
Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Musculoskeletal and joint diseases
June 2015
AbataceptOrencia ® Juvenile idiopathic arthritis in children and young people (NICE TA373)
Musculoskeletal system
January 2016
AbataceptOrencia®
Rheumatoid arthritis, 1st line biologic (NICE TA375) and (LMMG RA Biologic Pathway)
Musculoskeletal system
February 2016
AbataceptOrencia®Rheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA195) and (LMMG RA Biologic Pathway)Musculoskeletal and joint disease
updated April 2017
AcitretinOral Retinoid for Psoriasis
Skin
May 2013
AclidiniumEklira Genuair®

COPD
Respiratory System
November 2017
Aclidinium/FormoterolDuaklir® Genuair®

COPD
Respiratory System
November 2017
Actipatch®Actipatch®
Treatment of pain in knee osteoarthritis, plantar fasciitis and sub-muscular breast surgery
Musculoskeletal system
June 2018
AdalimumabHumira®
Rheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA195)
Musculoskeletal and joint disease
updated February 2016
AdalimumabHumira®
Crohn’s disease, 1st line biologic (NICE TA187) and LMMG Recommendation

Gastro-intestinal System
May 2016
AdalimumabHumira®
Severe plaque psoriasis (NICE TA146)
Skin
May 2013
AdalimumabHumira®
Ankylosing spondylitis (NICE TA383)
Musculoskeletal & Joint Diseases
updated March 2016
AdalimumabHumira®
Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy .
Musculoskeletal and joint diseases
November 2014
AdalimumabHumira®
Psoriatic arthritis (NICE TA199)Musculoskeletal and joint diseaseMay 2013
AdalimumabHumira®Juvenile idiopathic arthritis in children and young people (NICE TA373)
Musculoskeletal system
January 2016
AdalimumabHumira®
Rheumatoid arthritis, 1st line biologic (NICE TA375) and (LMMG RA Biologic Pathway)
Musculoskeletal system
February 2016
AdalimumabHumira®
Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Musculoskeletal & joint diseases
June 2015
AdalimumabHumira®
Non-radiographic axial spondyloarthritis (NICE TA383)
Musculoskeletal & Joint Diseases
updated March 2016
AdalimumabCrohn’s disease, 2nd line biologic (NICE TA187) and LMMG Recommendation
Gastro-intestinal system
May 2016
AdalimumabHumira®
Use in high risk patients for prevention of recurrence or upon recurrence of Crohn’s Disease following surgery.

Gastro-intestinal system
May 2016
AdalimumabHumira®
Second line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LMMG Recommendation
Gastro-intestinal system
May 2016
AdalimumabHumira®Prevention of recurrence of ulcerative colitis following surgeryGastro-intestinal systemMay 2016
AdalimumabHumira®
Treating moderate to severe hidradenitis suppurativa (NICE TA392)
SkinJuly 2016
AdalimumabHumira®
Treating non-infectious uveitis (NICE TA460)
Eye
September 2017
AdalimumabHumira®
Treating plaque psoriasis in children and young people (NICE TA455)
Skin
September 2017
AdalimumabHumira®
First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LMMG Recommendation

Gastro-intestinal System
May 2016
Adefovir DipivoxilChronic Hepatitis B (NICE TA96)
Infections
November 2013
AdenosineSupraventricular arrhythmias
Cardiovascular SystemOctober 2014
AfliberceptEylea®
Macular oedema secondary to central retinal vein occlusion (NICE TA305)
EyeMarch 2014
AfliberceptEylea®Diabetic Macular Oedema (NICE TA346)
EyeSeptember 2015
AfliberceptEylea ®
Visual impairment caused by macular oedema after branch retinal vein occlusion (NICE TA409)
EyeOctober 2016
AfliberceptEylea®
Treating choroidal neovascularisation (NICE TA486)
Eye
November 2017
AfliberceptEylea ®
Wet age-related macular degeneration (NICE TA294)EyeOctober 2013
AgomelatineMajor depressive episodes (NICE TA231 — terminated appraisal)Central Nervous System
May 2013
AlbiglutideEperzan ®
Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control
Endocrine system
March 2016
Lenvatinib and sorafenibLenvima® and Nexavar®
for treating differentiated thyroid cancer after radioactive iodine
Immune system and Malignant Disease
September 2018
AlemtuzumabMultiple sclerosis (relapsing-remitting) (NICE TA312)
Malignant disease and immunosuppression
June 2014
Alendronic acidOsteoporosis (NICE TA464)
Endocrine System
September 2017
AlirocumabPraluent®Treating primary hypercholesterolaemia and mixed dyslipidaemia (NICE TA393)
Cardiovascular SystemJuly 2016
AliskirenRasilez®Essential hypertensionCardiovascular systemJuly 2019
AlitretinoinSevere, chronic hand eczema (NICE TA177)
Skin
May 2013
AllopurinolGout (as per LMMG Guidelines)
Musculoskeletal system
January 2016
AlogliptinVipidia ®
Type 2 diabetes
Endocrine System
February 2018
AlprazolamAnxiety (short term use)
Central Nervous System
May 2013
Alprostadil CreamVitaros®
Erectile Dysfunction in patients who are intolerant to or have a contra-indication to PDE5 inhibitorsGenito-urinary systemSeptember 2015
Alprostadil CreamVitaros®Erectile Dysfunction in patients who have not responded to at least 2 other PDE5 inhibitorsGenito-urinary system
September 2015
Alprostadil intracavernosal injectionCaverject ® Viridal ® Duo
Erectile Dysfunction
Genito-urinary systemSeptember 2015
Alprostadil Urethral applicationMUSE ®
Erectile Dysfunction
Genito-urinary systemSeptember 2015
AlprostadilCaverject®
Ductus arteriosus patencyGenito-urinary systemOctober 2014
AlteplaseAcute ischaemic stroke (NICE TA264)
Cardiovascular SystemMay 2013
AlteplaseActilyse®Massive pulmonary embolismCardiovascular SystemMarch 2014
AlteplaseThrombolysis in MI (NICE TA52)
Cardiovascular SystemMay 2013
AmantadineSymmetrel®
Parkinson’s disease (but not drug-induced extrapyramidal symptoms)Central Nervous System
October 2014
AmantadineLysovir®
Influenza treatment & prophylaxis (NICE TA158 & 168)
Infections
May 2013
AmbrisentanPulmonary hypertension
Cardiovascular SystemMay 2013
Amiodarone (tablets)Arrhythmias
Cardiovascular SystemNovember 2013
AmisulprideSchizophrenia
Central Nervous System
May 2013
AmitriptylineNeuropathic pain (as per LMMG Guidelines)
Central Nervous system
December 2015
AmitriptylineMigraine prophylaxis, Tension Type Headache prophylaxis
Central Nervous SystemMay 2016
AmitriptylineDepressive illnessCentral Nervous SystemMarch 2015
AmobarbitalSevere intractable insomnia only in patients already taking barbiturates
Central Nervous System
May 2013
Amphotericin (Lipid Formulations)Abelcet ® AmBisome ® Systemic fungal infections
Infections
October 2014
AmphotericinFungizone ®
Systemic fungal infections
Infections
October 2014
AnagrelideEssential thrombocythaemia in patients at risk of thrombo-haemorrhagic events who have not responded adequately to other drugs or who cannot tolerate other drugsNutrition and Blood
May 2013
AnakinraRheumatoid arthritis
(CG79)
Musculoskeletal and joint disease
May 2013
AnastrozoleHormonal treatment for early breast cancer (NICE TA112)
Malignant Disease and ImmunosuppressionMay 2014
Antibiotics (intravenous)All indications
InfectionsOctober 2014
ApixabanEliquis®Prevent of stroke and systemic embolism in people with nonvalvular atrial fibrillation (NICE TA275)
Cardiovascular SystemJuly 2014
ApixabanEliquis®Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA 341)
Cardiovascular SystemJuly 2015
ApixabanEliquis®Prevention of venous thromboembolism after total hip or knee replacement in adults (NICE TA245)
Cardiovascular SystemJuly 2014
ApomorphineParkinson’s disease
Central Nervous System
April 2016
ApremilastOtezla®Active psoriatic arthritis (NICE TA433)Musculoskeletal systemMarch 2017 (updated)
ApremilastOtezla®
Moderate to severe plaque psoriasis (NICE TA419)
Skin
December 2016 (updated)
Aquamax ®Aquamax ® Emollient preparationSkinApril 2013
AripiprazoleAbilify®Bipolar disorder
(NICE TA292)
Central Nervous System
October 2013
AripiprazoleAbilify ®Bipolar disorder in AdultsCentral Nervous System
October 2013
Aripiprazole prolonged-release suspension for injectionAbilify Maintena®
Maintenance treatment of schizophrenia in adult patients
Central Nervous System
January 2016
AripiprazoleAbilify®Schizophrenia (NICE TA213)
Central Nervous System
May 2013
AsenapineAcute ManiaCentral Nervous System
May 2013
Aspirin dispersibleAcute MigraineCentral Nervous SystemMay 2016
AspirinSecondary Prevention of stroke (as per LMMG Guidelines)
Cardiovascular SystemJanuary 2016
AtomoxetineADHD in children, adolescents and adults (NICE TA98)
Central Nervous System
Dec 2014
AvanafilSpedra ®
Erectile dysfunctionGenito-urinary systemOctober 2015
Aviptadil / Phentolamine Mesilate InjectionInvicorp ®For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology.Genito-urinary systemMay 2017
AzathioprineInflammatory bowel disease, Rheumatic diseases, Dermatology
Gastro-intestinal System, Musculoskeletal and joint disease, Skin
May 2013
Azelastine hydrochloride 137 microgram/Fluticasone propionate 50 microgram (120d)Dymista ®
Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
Ear, Nose & Oropharynx
May 2019
Baclofen IntrathecalSpasticity
Musculoskeletal and joint disease
May 2013
Balsalazide SodiumTreatment of mild to moderate ulcerative colitis and maintenance of remission
Gastro-intestinal System
November 2013
BaricitinibOlumiant®
Moderate to severe rheumatoid arthritis (NICE TA466)
Musculoskeletal system
September 2017
BasiliximabSimulect®
Immunosuppresive therapy for kidney transplant in children and young people (NICE TA482)
Immune system and Malignant Disease
November 2017
BasiliximabSimulect®
Immunosuppresive therapy for kidney transplant in adults (NICE TA481)Immune system and Malignant Disease
November 2017
Bath & Shower PreparationsDry & Pruritic Skin ConditionsSkinJuly 2019
Bazedoxifene / conjugated oestrogenDuavive®Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriateEndocrine SystemDecember 2016
Beclomethasone / formoterol / glycopyrronium bromideTrimbow®
Maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2‑agonistRespiratory systemOctober 2017
Beclomethasone/FormoterolFostair®
COPDRespiratory system
November 2017
BelimumabBenlysta®
Treating active autoantibody-positive systemic lupus erythematosus (NICE TA397)

Malignant Disease

May 2013
BenperidolControl of deviant antisocial sexual behaviour
Central Nervous System
May 2013
BenralizumabFor treating severe eosinophilic asthmaRespiratory SystemApril 2019
Berinert c1 inhibitorAcute attacks of hereditary angiodema
Respiratory System
May 2013
Betamethasone with CalcipotriolPsoriasisSkinMay 2017
Betamethasone with salicylic acidPsoriasisSkinMay 2017
Betamethasone (Topical)Psoriasis
SkinMay 2017
BetamethasonePsoriasisSkinMay 2017
Bethanechol ChlorideMyotonine®
Urinary retention
Genito-urinary systemOctober 2014
BevacizumabAvastin®
Ophthalmic Use
EyeOctober 2014
Biphasic insulin (human)Humulin M3 KwikPen ®
Insuman Comb 25 SoloStar ®
Type 1 and type 2 diabetes mellitus
Endocrine SystemFebruary 2018
Biphasic insulin (Short-acting analogues)Novomix 30 FlexPen ®
Humalog Mix KwikPen ®
Type 1 and type 2 diabetes mellitus
Endocrine System
February 2018
BisacodylConstipation in adults
Gastro-intestinal System
November 2016
BivalirudinMI with persistent ST-segment elevation (NICE TA230)
Cardiovascular SystemMay 2013
BoceprevirTreatment of genotype 1 chronic hepatitis C (NICE TA253)
Infections
July 2014
BosentanPulmonary hypertension
Cardiovascular SystemMay 2013
Botulinum Toxin Type Afor the treatment of chronic migraine (NICE TA260)
Central Nervous System
May 2013
Botulinum Toxin Type ACosmetic procedures
Central Nervous System
April 2018
Botulinum Toxin Type AAll brands within licensed indications only
Focal Spasticity in multiple sclerosis
Central Nervous SystemMarch 2014
Botulinum Toxin Type AHyperhidrosis due to social anxiety disorder
Central Nervous System
March 2014
Botulinum Toxin Type AAll brands within licensed indications only
Contracture of the joint in multiple sclerosis
Central Nervous SystemMarch 2014
Botulinum Toxin Type ADetrusor overactivity — urology (CG171)
Central Nervous SystemMarch 2014
Botulinum Toxin Type AFocal spasticity, Hand and wrist disability associated with stroke, Blepharospasm, Hemifacial spasm, Spasmodic torticollis
Central Nervous System
March 2014
BrimonidineMirvaso®Treatment of facial erythema of rosacea in adults 18 years and over
Skin
September 2014
Brimonidine (eye drops)Raised intra-ocular pressure
EyeOctober 2014
Brinzolamide (eye drops)Azopt®
Reduction of intra-ocular pressure
EyeOctober 2014
BrivaracetamBriviact ® EpilepsyCentral Nervous system
September 2016
BrodalumabKyntheum®
Treating moderate to severe plaque psoriasis (NICE TA511)
SkinApril 2018
BromocriptineParkinson’s disease
Central Nervous System
October 2014
Budesonide multimatrixCortimentFor induction of remission in adults with mild to moderate active ulcerative colitis where 5‑ASA (aminosalicylate) treatment is not sufficient.Gastro-intestinal systemMay 2017
Budesonide/FormoterolSymbicort®
COPDRespiratory system
November 2017
Buprenorphine patchesPainCentral Nervous System

March 2015
Buprenorphine sublingual tabletsSubutex® Opioid Dependence (NICE TA114)
Central Nervous System
February 2015
BuspironeAnxiety (short term use)
Central Nervous System
May 2013
ButobarbitalSevere intractable insomnia only in patients already taking barbiturates
Central Nervous System
May 2013
CabergolineHyperprolactinaemia
Endocrine SystemOctober 2014
CabergolineParkinson’s disease
Central Nervous System
November 2013
CalcipotriolPsoriasisSkinMay 2017
Calcitonin (injection)Miacalcic®Prevention of sudden bone loss due to sudden immobility
Endocrine SystemOctober 2014
Calcitonin (injection)Miacalcic®HypercalcaemiaEndocrine SystemMay 2013
Calcium acetate tabletsHyperphosphataemia associated with renal failure
Nutrition and Blood
October 2014
Calcium Acetate/Heavy Magnesium CarbonateOsvaren®
Phosphate binder — renal dialysis
Nutrition and Blood
July 2014
Calcium folinate (injection)Methotrexate induced mucosistis or myelosuppression
Musculoskeletal and joint disease
October 2014
Calcium and Vitamin DCalcichew D3 Forte ®
Following a gastric bypass
Nutrition and Blood
March 2017
Calcium and Vitamin DCalcichew D3 Forte ®
Following bariatric surgery performed privately
Nutrition and Blood
March 2017
Calcium and Vitamin DCalcichew D3 Forte ®
Following a sleeve gastrectomy
Nutrition and Blood
March 2017
CanagliflozinInvokana®Monotherapy for treating type 2 diabetes (NICE TA390)Endocrine SystemJune 2016
CanagliflozinInvokana®
In combination therapy for treating type 2 diabetes (NICE TA315)
Endocrine System
July 2014
CanakinumabIlaris®
Juvenile idiopathic arthritis (systemic) (NICE TA302)Musculoskeletal and joint disease
December 2013
CanakinumabGouty arthritis (NICE 281 — terminated appraisal)Musculoskeletal and joint disease
April 2013
CangrelorReducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (NICE TA351 — terminated appraisal)Cardiovascular SystemSeptember 2015
Cannabis ExtractSativex®
Adjunct in moderate to severe spasticity in multiple sclerosis
Musculoskeletal and joint disease
October 2014
CapreomycinAntituberculosis drug
Infections
October 2014
Capsaicin cream 0.025%Hand and Knee Osteoarthritis (as per LMMG Guidelines)
Central Nervous System
January 2016
Capsaicin creamLocalised neuropathic pain (as per LMMG Guidelines)
Central Nervous system
December 2015
Carbamazepine (tablets, liquids and suppositories)Prophylaxis of bipolar disorder unresponsive to lithium
Central Nervous System
May 2013
CarbamazepineTrigeminal Neuralgia (as per LMMG Guidelines)
Central Nervous system
December 2015
CarboprostHemabate®
Postpartum haemorrhage
Genito-urinary systemOctober 2014
CariprazineReagila ®Treatment of schizophrenia in adult patientsCentral nervous systemApril 2019
Certolizumab pegolCimzia®
Ankylosing spondylitis (NICE TA383)
Musculoskeletal & Joint Diseases
updated March 2016
Certolizumab pegolModerate to severe Plaque PsoriasisSkinMay 2019
Certolizumab pegolCimzia®
Rheumatoid arthritis, 1st line biologic (NICE TA375) and (LMMG RA Biologic Pathway)
Musculoskeletal system
February 2016
Certolizumab pegolCimzia®
Non-radiographic axial spondyloarthritis (NICE TA383)
Musculoskeletal & Joint Diseases
updated March 2016
Certolizumab pegolCimzia®
Crohn’s disease
Gastro-intestinal system
May 2016
Certolizumab pegolCimzia®
Ulcerative Colitis
Gastro-intestinal system
May 2016
Certolizumab pegolCimzia ®
Rheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA415) and (LMMG RA Biologic Pathway)Musculoskeletal system
updated April 2017
Certolizumab pegolCimzia®Certolizumab pegol for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)Musculoskeletal systemJune 2017
Chloral HydrateInsomnia (short term use)Central Nervous SystemMay 2013
ChlordiazepoxideAnxietyCentral Nervous SystemMarch 2015
ChlordiazepoxideAlcohol withdrawal
Central Nervous System
updated Nov 2016
Chlorpromazine injectionSchizophrenia and other psychoses, mania, anxiety, agitation, violent or dangerously impulsive behaviour, childhood schizophrenia
Central Nervous System
May 2013
Chlorpromazine (Tablets/Liquids and suspension)Schizophrenia and other psychoses, mania, anxiety, agitation, violent or dangerously impulsive behaviour, childhood schizophreniaCentral Nervous SystemMarch 2015
Ciclosporin 0.1% / 1 mg/mL eye drops Verkazia®
Severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.
Eye
May 2019
CiclosporinIkervis®
Dry eye disease that has not improved despite treatment with artificial tears (NICE TA369)
EyeJanuary 2016
Ciclosporin (capsules and solution)For prophylaxis of graft rejection following organ transplantationMalignant Disease and Immunosuppression
May 2017
Ciclosporin (injection)Severe acute ulcerative colitis
Gastro-intestinal System
October 2014
Ciclosporin (injection)For prophylaxis of graft rejection following organ transplantationMalignant disease and immunosuppression
May 2017
CiclosporinRheumatic diseases, dermatology and severe ulcerative colitis
Musculoskeletal and Joint Diseases, Skin, Gastro-intestinal system
October 2014
CidofovirVistide®
Cytomegalovirus retinitis in AIDS patients
Infections
October 2014
CilostazolPeripheral arterial disease (NICE TA223)
Cardiovascular SystemMay 2013
CinacalcetTreatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (NICE TA117)
Nutrition and Blood
July 2014
Cinryze c1 inhibitorAcute attacks of hereditary angiodema
Respiratory system
May 2013
CitalopramDepressive illness, panic disorderCentral Nervous SystemMarch 2015
CitalopramPremature ejaculation
Genito-urinary systemJanuary 2015
CladribineMavenclad®
Treating relapsing–remitting multiple sclerosis (NICE TA493)
Immune system and malignant disease
January 2018
ClobazamAdjunct in epilepsyCentral Nervous System
October 2014
ClobetasolPsoriasisSkinMay 2017
ClobetasonePsoriasisSkinMay 2017
ClomifeneAnovulatory infertility
Endocrine SystemNovember 2013
Clomipramine capsulesDepressive illness, phobic and obsessional statesCentral Nervous SystemMarch 2015
Clomipramine mr tabletsDepressive illness, phobic and obsessional states
Central Nervous System
May 2013
ClonazepamAnxietyCentral Nervous System
March 2015
ClonazepamMood disordersCentral Nervous SystemMarch 2015
ClonazepamAll forms of epilepsy
Central Nervous System
October 2014
ClonidineADHDCentral Nervous System
March 2015
ClonidineTourette syndrome (unlicensed indication)
Central Nervous System
October 2014
ClopidogrelPrevention of occlusive vascular events (NICE TA210)
Cardiovascular SystemJuly 2014
ClopidogrelTreatment of unstable angina and N‑STEMI (NICE CG94 and CG172)
Cardiovascular Systemupdated February 2016
ClozapineTreatment resistant/intolerant schizophrenia
Central Nervous System
May 2013
Co–careldopa/ EntacaponeStalevo®Parkinson’s disease
Central Nervous System
October 2014
Co-proxamolPainCentral Nervous System
October 2014
Co-trimoxazoleLow dose prophylaxis of pneumocystis jirovecii (Pneumocystis carinii) infections post-transplant
Infection
November 2017
Co-trimoxazoleSubacute bacterial perotinitis prophylaxis
InfectionsApril 2016
Coal tar with Salicylic acid and Sulfur precipitated PsoriasisSkinMay 2017
CodeinePainCentral Nervous System
January 2016
ColchicineAcute Gout (as per LMMG Guidelines)
Musculoskeletal system
January 2016
ColesevelamCholestagel®Combination and monotherapy for familial hypercholesterolaemia
Cardiovascular SystemSeptember 2016
ColesevelamOff licence use for intractable diarrhoea under specialist gastroenterology guidance only
Gastro-intestinal System
November 2013
Colistimethate nebulisedwhen inhaled for Cystic fibrosis
Infections
October 2014
Colistimethate Sodium (Dry Powder for Inhalation)Colobreathe ®
Cystic fibrosis (pseudomonas lung infection) (NICE TA276)
Infections
October 2013
Colistimethate sodium/Colistin sulfomethateColomycin®
Non-cystic fibrosis bronchiectasisInfections
October 2015
Collagenase clostridium histolyticumXiapex®
Treating Dupuytren’s contracture (NICE TA459)
Musculoskeletal system
September 2017
Conestat AlfaAcute attacks of hereditary angiodema
Respiratory systemMay 2013
CyclophosphamideRheumatic disease
Musculoskeletal and joint disease

October 2014
CycloserineAntituberculosis drug
Infections
October 2014
DabigatranPradaxa® Prevention of stroke and systemic embolism in atrial fibrillation (NICE TA249)
Cardiovascular SystemJuly 2014
DabigatranPradaxa®Treatment of deep vein thrombosis and/or pulmonary embolism
Cardiovascular SystemJanuary 2015
DabigatranPradaxa® Prevention of venous thromboembolism after hip or knee replacement surgery in adults (NICE TA157)
Cardiovascular SystemJuly 2014
DaclatasvirDaklinza®
Chronic hepatitis C (NICE TA364)
InfectionsDecember 2015
DapagliflozinForxiga®Monotherapy for treating type 2 diabetes (NICE TA390)Endocrine SystemJune 2016
DapagliflozinForxiga®Triple therapy for treating type 2 diabetes (NICE TA418)Endocrine SystemDecember 2016
DapagliflozinForxiga®In combination therapy for treating type 2 diabetes
(NICE TA288)
Endocrine SystemDecember 2016 (updated)
DapoxetineTreatment of premature ejaculation (PE) in men 18–64 years of age
Central Nervous System
January 2015
DarbepoetinCancer treatment induced anaemia (NICE TA323)Nutrition and Blood
May 2013
DarifenacinEmselex®
Urinary frequency, urgency, and incontinence
Genito-urinary systemFebruary 2015
DarvadstrocelDarvadstrocel for treating complex perianal fistulas in Crohn’s disease (TA556)Gastro-intestinal systemFebruary 2019
DeferiproneIron Overload
Nutrition and Blood
May 2013
DeflazacortCalcort®Suppression of inflammatory and allergic disorders
Endocrine SystemOctober 2014
DegarelixFirmagon ®
Treatment of advanced hormone-dependent prostate cancer (NICE TA404)
Malignant Disease
September 2016
Demeclocycline hydrochlorideHyponatraemia
Endocrine System
October 2014
DenosumabXgeva®
Bone metastasis from solid tumours (NICE TA265)
Endocrine System
May 2013
DenosumabProlia®
Prevention of osteoporotic fractures in postmenopausal women (NICE TA204)
Endocrine System
November 2013
DenosumabProlia®
Glucocorticoid-induced osteoporosisEndocrine SystemMay 2018
DenosumabProlia®
Prevention of osteoporotic fractures in men
Endocrine System
February 2018
Desferrioxamine mesilateIron Overload
Nutrition and Blood
May 2013
Dexamethasone implantDiabetic Macular Oedema (NICE TA349)
EyeSeptember 2015
Dexamethasone implantOzurdex®
Treating non-infectious uveitis (NICE TA460)
Eye
September 2017
Dexamethasone implantMacular Oedema — retinal vein occlusion (NICE TA229)
Eye
May 2013
DexamfetamineADHD in children, adolescents and adults (NICE TA98)
Central Nervous System
December 2014
DiazepamAnxietyCentral Nervous SystemMarch 2015
DiflucortolonePsoriasisSkinMay 2017
Digoxin immune fabDigiFab®Digoxin antidoteCardiovascular SystemMarch 2014
DihydrocodeinePainCentral Nervous System
January 2016
Dimethyl fumarateSkilarence®
Treating moderate to severe plaque psoriasis (NICE TA475)
SkinOctober 2017
Dimethyl FumarateTreating relapsing‑remitting multiple sclerosis (NICE TA320)
Malignant disease and immunosuppression
September 2014
Dipyridamole modified releasePrevention of occlusive vascular events (NICE TA210)
Cardiovascular SystemJuly 2014
DistigmineUrinary retention
Genito-urinary systemOctober 2014
DisulfiramAntabuse®Adjunct in the treatment of alcohol dependence (under specialist supervision)
Central Nervous System
October 2014
Docusate sodiumConstipation in adults
Gastro-intestinal System
November 2016
DomperidoneNausea associated with acute migraine
Central Nervous SystemMay 2016
DonepezilAlzheimer’s Disease (NICE TA217)
Central Nervous System
March 2015
DosulepinDepressive illness
Central Nervous System
May 2013
Doxazosin modified releaseHypertension, Benign Prostatic Hyperplasia
Cardiovascular System
November 2017
Doxepin capsulesDepressive illnessCentral Nervous SystemMarch 2015
DoxepinPsychosis in Parkinson’s disease
Central Nervous System
May 2013
Doxylamine and pyridoxineXonvea®
Moderate-to-severe nausea and vomiting in pregnancy in women who do not adequately respond to conservative management
Central Nervous System
October 2018
DronedaroneTreatment of non-permanent atrial fibrillation (NICE TA197)
Cardiovascular SystemJuly 2014
DulaglutideTrulicity ®
In adults with type 2 diabetes mellitus to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.Endocrine System
March 2016
DuloxetineCymbalta®Depressive illness, generalised anxiety disorder
Central Nervous System
May 2013
DuloxetineNeuropathic pain (as per LMMG Guidelines)
Central Nervous system
December 2015
DupilumabDupixent®
for treating moderate to severe atopic dermatitis
SkinSeptember 2018
DutasterideAvodart®
Benign prostatic hyperplasia
Endocrine System
October 2014
EdoxabanLixiana®Prevention of stroke and systemic embolism in non-valvular atrial fibrillation (NICE TA355)
Cardiovascular SystemOctober 2015
EdoxabanTreating and preventing deep vein thrombosis and pulmonary embolism (NICE TA354)
Cardiovascular SystemSeptember 2015
EflornithineFacial hirsutism
Skin
March 2017
Elbasvir–grazoprevirZepatier ®
Chronic Hepatitis C (NICE TA413)
Infections
November 2016
Electronic-cigarettes (e‑cigarettes)e‑Voke ® To relieve and/or prevent withdrawal symptoms and reduce the cravings associated with tobacco dependence
Central Nervous system
September 2016
EltrombopagRevolade®
Treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal NICE TA382)
Nutrition and Blood
February 2016
EltrombopagRevolade ®
Treatment of thrombocytopenia in adults with hepatitis C
Nutrition and Blood
May 2014
EltrombopagRevolade®
Thrombocytopenic purpura (NICE TA293)
Nutrition and Blood
October 2013
EluxadolineTruberzi®
Treating irritable bowel syndrome with diarrhoea (NICE TA471)
Malignant Disease
September 2017
EmpagliflozinJardiance®Monotherapy for treating type 2 diabetes (NICE TA390)Endocrine SystemJune 2016
EmpagliflozinJardiance®In combination therapy for treating type 2 diabetes (NICE TA336)

Endocrine SystemApril 2015
EntacaponeAdjunct to co-beneldopa or co-careldopa in Parkinson’s disease
Central Nervous System
October 2014
EntecavirTreatment of chronic hepatitis B (NICE TA153)
Infections
July 2014
EplerenoneHeart Failure (as per the product license)
Cardiovascular Systemupdated February 2016
Epoprostenol ivPulmonary hypertension
Cardiovascular SystemMay 2013
ErenumabAimovig®Prophylaxis of migraineCentral Nervous SystemJune 2019
Ertugliflozin with metformin and a dipeptidyl peptidase‑4 inhibitorTreating type 2 diabetes (NICE TA583)Endocrine systemJuly 19
ErtugliflozinSteglatro® Type 2 Diabetes MellitusEndocrine SystemMarch 2019
Erythropoietin alfa and betaCancer treatment induced anaemia (NICE TA323)
Nutrition and Blood
May 2013
ErythropoietinsSymptomatic Anaemia associated with renal failure or in patients receiving cytotoxic chemotherapy
Nutrition and Blood
October 2014
EscitalopramMajor Depressive illness
Central Nervous System
May 2013
EscitalopramGeneralised anxiety disorder

Central Nervous System
May 2013
EslicarbazepineZebinix® Adjunctive therapy in patients with partial-onset seizures with or without secondary generalisation
Central Nervous System
December 2014
EtanerceptEnbrel®, Benepali®
Severe Plaque Psoriasis (NICE TA103)SkinMay 2013
EtanerceptEnbrel®, Benepali®
Rheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA195) and (LMMG RA Biologic Pathway)Musculoskeletal and joint diseaseupdated April 2017
EtanerceptEnbrel®, Benepali®
Ankylosing spondylitis (NICE TA383)
Musculoskeletal & Joint Diseases
updated March 2016
EtanerceptEnbrel®, Benepali®
Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy .
Musculoskeletal and joint diseases
Nov 2014
EtanerceptEnbrel®, Benepali®Psoriatic arthritis (NICE TA199)Musculoskeletal and joint diseaseMay 2013
EtanerceptEnbrel®, Benepali®
Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Musculoskeletal and joint diseaseJune 2015
EtanerceptEnbrel®, Benepali®Juvenile idiopathic arthritis in children and young people (NICE TA373)
Musculoskeletal system
January 2016
EtanerceptEnbrel®, Benepali®
Rheumatoid arthritis, 1st line biologic (NICE TA375) and (LMMG RA Biologic Pathway)
Musculoskeletal system
February 2016
EtanerceptEnbrel®, Benepali®
Non-radiographic axial spondyloarthritis (NICE TA383)
Musculoskeletal & Joint Diseases
updated March 2016
EtanerceptEnbrel® Benepali®
Treating plaque psoriasis in children and young people (NICE TA455)
Skin
September 2017
EtelcalcetideParsabiv ® Etelcalcetide for treating secondary hyperparathyroidism (NICE TA448)Endocrine SystemJuly 2017
Ethambutol hydrochlorideTuberculosis, in combination with other drugs
Infections
October 2014
EthosuximideEpilepsyCentral Nervous System
October 2014
EtidronateDidronel® Primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA160 &161)Endocrine SystemMarch 2015
EvolocumabRepatha®Prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin
Cardiovascular System
July 2018
EvolocumabRepatha®Treating primary hypercholesterolaemia and mixed dyslipidaemia (NICE TA394)
Cardiovascular SystemJuly 2016
ExemestaneHormonal treatment for early breast cancer (NICE TA112)Malignant Disease and ImmunosuppressionMay 2014
ExenatideType 2 diabetes (NICE NG 28)
Endocrine SystemMay 2013
EzetimibePrimary heterozygous-familial and non-familial hypercholesterolaemia (NICE TA385)
Cardiovascular SystemMarch 2016
FebuxostatHyperuricaemia in people with gout (NICE TA164)
Musculoskeletal and joint disease
February 2015
Fentanyl immediate releaseNon cancer painCentral Nervous SystemDecember 2017
Fentanyl (patches)Pain (as per LMMG Position Statement)
Central Nervous System
January 2016
Ferric MaltolFeraccru®Iron Deficiency Anaemia in Adult Patients with Inflammatory Bowel DiseaseNutrition and BloodMay 2017
Ferrous sulphate, fumarate and gluconateFollowing a gastric bypass
Nutrition and Blood
March 2017
Ferrous sulphate, fumarate and gluconateFollowing bariatric surgery performed privately
Nutrition and Blood
March 2017
Ferrous sulphate, fumarate and gluconateFollowing a sleeve gastrectomy
Nutrition and Blood
March 2017
FinasterideBenign prostatic hyperplasiaEndocrine SystemJuly 2016
FingolimodRelapsing remitting multiple sclerosis (NICE TA254)
Malignant disease and immunosuppression
May 2013
Flecainide (oral)ArrhythmiasCardiovascular SystemNovember 2013
Fluocinolone acetonide PsoriasisSkinMay 2017
Fluocinolone Acetonide Intravitreal ImplantIluvien®
Diabetic macular oedema (NICE TA301)Eye
December 2013
FluoridesProphylaxis of dental caries
Nutrition and Blood
April 2013
Fluorouracil 0.5%, Salicylic acid 10% solution (Actikerall®)Actikerall®
Treatment of Actinic Keratosis
Skin
September 2013
Fluorouracil cream 5%Efudix®
Treatment of small superficial basal-cell carcinomas in adults

Skin
May 2018
FluoxetineDepressive illness
Bulimia nervosa, obsessive compulsive disorder
Central Nervous SystemMarch 2015
FluoxetinePremature ejaculationGenito-urinary systemJanuary 2015
Flupentixol (as dihydrochloride)Depressive illness, psychoses
Central Nervous System
May 2013
Flupentixol DecanoateSchizophreniaCentral Nervous SystemMay 2013
FluphenazineMaintenance in schizophrenia and other psychoses
Central Nervous System
May 2013
FlurazepamInsomnia (short term use)
Central Nervous System
May 2013
Fluticasone furoate/Umeclidinium/Vilanterol (Trelegy®)Trelegy®
COPD
Respiratory system
January 2018
Fluticasone Furoate/VilanterolRelvar® Ellipta®
Asthma in children aged 12 to 16 years
Respiratory System
January 2015
Fluticasone Furoate/VilanterolRelvar® Ellipta®Asthma in adults aged 17 and overRespiratory SystemFebruary 2019
Fluticasone Furoate/VilanterolRelvar® Ellipta®COPDRespiratory SystemNovember 2017
FluvoxamineDepressive illness, obsessive compulsive disorder
Central Nervous System
May 2013
FomepizoleAntizol®Emergency treatment of poisoning (Ethylene glycol and methanol)
March 2014
Forceval ®Forceval ®
Following a gastric bypass
Nutrition and Blood
March 2017
Forceval ®Forceval ®
Following bariatric surgery performed privately
Nutrition and Blood
March 2017
Forceval ®Forceval ®
Following an adjustable gastric band or sleeve gastrectomyNutrition and Blood
March 2017
Lidocaine/prilocaine cutaneous sprayFortacin® Treatment of primary premature ejaculation in adult menGenito-urinary systemFebruary 2019
Foscarnet sodiumFoscavir®
Cytomegalovirus disease
Infections
October 2014
FreeStyle LibreDiabetes monitoring
Endocrine System
October 2017
GabapentinRestless Legs Syndrome (off-licence as per LMMG Guidelines)
Central Nervous system
December 2015
GabapentinMigraine prophylaxis
Central Nervous SystemMay 2016
GabapentinNeuropathic pain (as per LMMG Guidelines)
Central Nervous system
December 2015
GalantamineAlzheimer’s Disease (NICE TA217)
Central Nervous System
March 2015
GanciclovirCymevene®
Treatment and prevention of cytomegalovirus disease
Infections
October 2014
GlatiramerCopaxone®
Multiple Sclerosis (NICE TA527)Immune system and Malignant Disease
July 2018
Glecaprevir-pibrentasvirMaviret®
Chronic hepatitis C in adults (NICE TA499)
Infection
February 2018
GliclazideType 2 diabetes
Endocrine System
February 2018
GlimepirideType 2 diabetes
Endocrine System
February 2018
Glucosamine and ChondroitinPain associated with osteoarthritis
Blood and Nutrition
November 2017
Glycerol suppositoriesConstipation in children
Gastro-intestinal System
November 2016
GolimumabSimponi®
Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line .
Gastro-intestinal system
July 2016
GolimumabSimponi®Rheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA225) and (LMMG RA Biologic Pathway)Musculoskeletal and joint diseaseupdated April 2017
GolimumabSimponi®Psoriatic arthritis (NICE TA220)Musculoskeletal and joint diseaseMay 2013
GolimumabSimponi®
First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LMMG RecommendationGastro-intestinal System
May 2016
GolimumabSimponi®
Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy .
Musculoskeletal and joint diseases
November 2014
GolimumabSimponi®
Rheumatoid arthritis, 1st line biologic (NICE TA225 & 375) and (LMMG RA Biologic Pathway)
Musculoskeletal system
February 2016
GolimumabSimponi®Prevention of recurrence of ulcerative colitis following surgeryGastro-intestinal systemMay 2016
GolimumabSimponi®
Non-radiographic axial spondyloarthritis (NICE TA497)
Musculoskeletal system
February 2018
GolimumabSimponi®Ankylosing spondylitis (NICE TA383)Musculoskeletal and joint disease
March 2016
Guanfacine Prolonged Release TabletsADHD in children and adolescents aged 6 to 17 years for whom stimulants are not suitable, not tolerated or have been shown to be ineffectiveCentral Nervous System
June 2016
GuselkumabTremfya®Treating moderate to severe plaque psoriasis (NICE TA521)
SkinJune 2018
Haloperidol decanoate injectionMaintenance in schizophrenia and other psychoses
Central Nervous System
May 2013
Haloperidol InjectionRapid TranquilisationCentral Nervous SystemMarch 2015
Haloperidol tablets/liquidSchizophrenia and other psychoses, mania, anxietyCentral Nervous SystemMarch 2015
Heparin (unfractionated)All licensed indications
Cardiovascular SystemMay 2013
HIV Medicines Abacavir, Alafenamide, Amprenavir, Atazanavir, Bictegravir, CalciumIndinavir, Cobicistat, Darunavir, Didanosine, Dolutegravir, Dolutegravir, Efavirenz, Emtricitabine, Enfuvirtide, Etravirine, Elvitegravir, Fosamprenavir, Lamivudine, Lopinavir, Maraviroc, Nelfinavir Mesilate, Nevirapine, Raltegravir, Rilpivirine, Ritonavir, Saquinavir Mesylate, Sodium Diethyldithiocarbamate, Stavudine, Tenofovir Disoproxil, Tipranavir, Zalcitabine, ZidovudineAgenerase®, Aptivus®, Atripla®, Biktarvy®, Celsentri®, Combivir®, Crixivan®, Descovy®, Edurant®, Emtriva®, Evotaz®, Fortovase®, Fuzeon®, Hivid®, Ictastan®, Imuthiol®, Intelence®, Invirase®, Isentress®, Juluca®, Kaletra®, Kivexa®, Norvir®, Kivexa®, Prezista®, Retrovir®, Reyataz®, Rezolsta®, Sustiva®, Telzir®, Tivicay®, Trizivir®, Truvada®, Tybost®, Videx®, Viracept®, Viramune®, Viread®, Vitekta®, Zeffix®, Zerit®, Ziagen®
HIV infectionInfectionsMay 2013
HoloclarTreating limbal stem cell deficiency after eye burns (NICE TA467)
September 2017
Hormone Therapy Gender DysphoriaEndocrine SystemJuly 2019
Hyaluronic acidOsteoarthritis
Malignant Disease and ImmunosuppressionSeptember 2015
Hydrocortisone (injection)Acute Gout (as per LMMG Guidelines)
Endocrine system
January 2016
Hydrocortisone modified releasePlenadren®
Treatment of adrenal insufficiency in adults.
Endocrine System
July 2013
HydrocortisonePsoriasisSkinMay 2017
HydroxycarbamideThe prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults suffering from symptomatic Sickle Cell Syndrome

Immune system and Malignant Disease
July 2018
HydroxycarbamidePsoriasis

Immune system and Malignant Disease
July 2018
HydroxycarbamideTreatment of essential thrombocythemia or polycythaemia vera with a high risk for thromboembolic complications

Immune system and Malignant Disease
July 2018
Hydroxychloroquine sulfateRheumatoid conditions, lupus erythematosus, dermatological conditions
Musculoskeletal and joint disease
October 2014
Hyoscine hydrobromideDrug induced extrapyramidal side effectsCentral Nervous System
July 2015
Ibandronic acid injection (Bondronat®)Bondronat®
Bone metastases, Hypercalcaemia of malignancy
Endocrine System
October 2014
Ibandronic acid injection (Bonviva®)Bonviva®
Treatment of post menopausal osteoporosis
Endocrine System
October 2014
Ibandronic acid oral (Bonviva®)Bonviva®Treatment of post menopausal osteoporosis
Endocrine SystemNovember 2013
Ibandronic acidOsteoporosis (NICE TA464)
Endocrine System
September 2017
IbuprofenAcute Gout (as per LMMG Guidelines)
Musculoskeletal system
January 2016
IbuprofenPainMusculoskeletal system
January 2016
Iloprost (iv)RaynaudsCardiovascular SystemMay 2013
Iloprost (nebulised)Pulmonary hypertension
Cardiovascular SystemMay 2013
ImipramineDepressive illnessCentral Nervous SystemMarch 2015
Imiquimod cream 3.75% (Zyclara®)Zyclara®
Treatment of Actinic Keratosis
SkinSeptember 2013
Imiquimod cream 5%Aldara ®
Treatment of small superficial basal-cell carcinomas in adults
Skin
May 2018
InfliximabRemicade®, Inflectra®, Remsima®

Crohn’s disease, 1st line biologic (NICE TA187) and LMMG RecommendationGastro-intestinal System
May 2016
InfliximabInflectra®, Remsima®
Ankylosing spondylitis (NICE TA383)Musculoskeletal and joint disease
March 2016
InfliximabRemicade®, Inflectra®, Remsima®

Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Musculoskeletal and joint disease
June 2015
InfliximabRemicade®, Inflectra®, Remsima®
Very severe plaque psoriasis (NICE TA134)SkinMay 2013
InfliximabRemicade®, Inflectra®, Remsima®

Acute exacerbations of Ulcerative Colitis (NICE TA163) Gastro-intestinal System
May 2013
InfliximabRemicade®, Inflectra®, Remsima®

Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy .
Musculoskeletal and joint diseases
November 2014
InfliximabRemicade®, Inflectra®, Remsima®

Psoriatic arthritis (NICE TA199)Musculoskeletal and joint diseaseMay 2013
InfliximabRemicade®, Inflectra®, Remsima®
Use in high risk patients for prevention of recurrence or upon recurrence of Crohn’s Disease following surgery.

Gastro-intestinal system
May 2016
InfliximabRemicade®, Inflectra®, Remsima®Crohn’s disease, 2nd line biologic (NICE TA187) and LMMG RecommendationGastro-intestinal systemMay 2016
InfliximabRemicade®, Inflectra®, Remsima®Prevention of recurrence of ulcerative colitis following surgeryGastro-intestinal systemMay 2016
InfliximabRemicade®, Inflectra®, Remsima®
Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line .
Gastro-intestinal system
July 2016
InfliximabRemicade® Inflectra® Remsima®
First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LMMG RecommendationGastro-intestinal System
May 2016
InfliximabRemicade®, Inflectra®, Remsima®

Rheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA195) and (LMMG RA Biologic Pathway)Musculoskeletal and joint disease
updated April 2017
InfliximabRemicade®, Inflectra®, Remsima®
Rheumatoid arthritis, 1st line biologic (NICE TA375) and (LMMG RA Biologic Pathway)Musculoskeletal system
February 2016
Ingenol mebutate gel (Picato®)Picato®
Treatment of Actinic Keratosis
SkinSeptember 2013
Inhaled CorticosteroidsTreatment of chronic asthma in adults and children aged 12 years and over (NICE TA138) and in children under the age of 12 years (NICE TA131)
Respiratory System
July 2014
Inositol NicotinatePeripheral vascular disease (NICE TA223)
Cardiovascular SystemMay 2013
Insulin AspartFiasp®
Treatment of diabetes mellitus in adults
Endocrine System
September 2017
Insulin AspartNovorapid FlexPen®Type 1 and type 2 diabetes mellitus
Endocrine System
February 2018
Insulin DegludecTresiba®
Type 1 DiabetesEndocrine System
January 2018
Insulin degludec plus liraglutideXultophy®Treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control, in combination with oral glucose-lowering medicinal products when these alone, or combined with basal insulin, do not provide adequate glycaemic control
Endocrine SystemApril 2015
Insulin DegludecTresiba®Type 2 DiabetesEndocrine SystemJanuary 2018
Insulin DetemirLevemir ®Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and aboveEndocrine SystemJune 2016
Insulin glargine biosimilar (Abasaglar®)Abasaglar®Type 1 and Type 2 diabetes mellitus
Endocrine SystemJanuary 2016
Insulin glargine (Lantus®)Lantus®Type 1 and Type 2 diabetes mellitus
Endocrine SystemJanuary 2016
Insulin glargine with lixisenatideSuliqua®Type 2 Diabetes Mellitus Endocrine SystemJune 2019
Insulin Glargine U 300Toujeo®Type 1 Diabetes mellitus
Endocrine SystemMarch 2016
Insulin Glargine U 300Toujeo®Type 2 Diabetes mellitus
Endocrine SystemMarch 2016
Insulin glulisineApidra SoloStar®

Type 1 and type 2 diabetes mellitus
Endocrine System
February 2018
Insulin lisproHumalog KwikPen®

Type 1 and type 2 diabetes mellitus
Endocrine System
February 2018
Interferon beta 1aMultiple Sclerosis (NICE TA527)
Immune system and Malignant Disease
July 2018
Interferon beta 1bExtavia®
Multiple Sclerosis (NICE TA527)
Immune system and Malignant Disease
July 2018
IsocarboxazidDepressive illnessCentral Nervous System
May 2013
Isoniazid (injection)Tuberculosis
Infections
October 2014
Isoniazid (oral)Tuberculosis
Infections
October 2014
Isophane insulin (human)Humulin I KwikPen®
Insulatard Penfill®
Type 1 and type 2 diabetes mellitus
Endocrine System
February 2018
Isotretinoin (oral)AcneSkinMay 2013
Ispaghula HuskConstipation in adults
Gastro-intestinal System
November 2016
IvabradineHeart failure (NICE TA267), and chronic angina
Cardiovascular SystemMay 2013
IvermectinSoolantra ®
Topical treatment of inflammatory lesions of rosacea (papulopustular) in adults
Infections
March 2016
IxekizumabTaltz®
Treatment of active psoriatic arthritis in adults after inadequate response to DMARDsMusculoskeletal system
September 2018
IxekizumabTaltz ®
Ixekizumab for treating moderate to severe plaque psoriasis (NICE TA442)
SkinMay 2017
Ketovite®Ketovite®
Patients on haemodialysis
Nutrition and Blood
February 2015
LacosamideVimpat®EpilepsyCentral Nervous System
October 2014
LamivudineZeffix ®
Chronic hepatitis B
Infections
November 2013
LamotrigineEpilepsyCentral Nervous System
October 2014
LamotrigineUnlicensed as a mood stabiliser
Central Nervous System
May 2013
LanthanumHyperphosphataemia (NICE CG157)
Nutrition and Blood
May 2013
Macrogol (Laxido Paediatric ®)Laxido Paediatric ®
Constipation in children
Gastro-intestinal System
November 2016
Ledipasvir / Sofosbuvir (Harvoni®)Harvoni®
Chronic hepatitis C (NICE TA363)
Infections
December 2015
LeflunomideRheumatic diseases
Musculoskeletal and joint disease
May 2013
LesinuradZurampic®
Treating chronic hyperuricaemia in people with gout (NICE TA506)
Musculoskeletal system
March 2018
LetrozoleHormonal treatment for early breast cancer (NICE TA112)Malignant Disease and ImmunosuppressionMay 2014
LevamisoleRoundworm infections (unlicensed)
Infections
October 2014
Levetiracetam infusionEpilepsyCentral Nervous System
October 2014
LevetiracetamEpilepsyCentral Nervous System
October 2014
LevomepromazineSchizophrenia (Existing Patients)
Central Nervous System
October 2016
LevomepromazineSchizophrenia (New Patients)
Central Nervous System
May 2013
LevonorgestrelJaydess ®

ContraceptionGenito-urinary systemJuly 2015
Lidocaine 5% medicated plastersVersatis®Use outside of the license of post-herpetic neuralgia for the treatment of localised neuropathic pain with predominance of allodynia and/or hyperalgesia and dysesthesias unresponsive to other neuropathic agents
AnaesthesiaFebruary 2016
Lidocaine 5% medicated plastersVersatis®Post Herpetic Neuralgia (as per LMMG Guidelines)
AnaesthesiaNovember 2015
LinaclotideConstella®

Moderate to severe irritable bowel syndrome with constipation
Gastro-intestinal System
June 2013
LinagliptinTrajenta®
Type 2 diabetes
Endocrine System
February 2018
LinezolidZyvox®
Pneumonia, skin and soft-tissue infections
Infections
October 2014
LiothyronineTertroxin®Liothyronine as an add-on treatment for refractory hypothyroidism despite adequate monotherapy with levothyroxineEndocrine SystemMay 2016
LiothyronineTertroxin®Prescribing by secondary or tertiary care specialists for the treatment of acute conditions where thyroid replacement is needed rapidly, for a limited period and/or where a drug with shorter half-life is requiredEndocrine SystemMay 2016
LiraglutideSaxenda®
Adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patientsEndocrine SystemJuly 2017
LiraglutideVictoza®Type 2 diabetes mellitus (NICE NG28)Endocrine SystemMay 2014
LisdexamfetamineElvanse Adult ®Adult ADHDCentral Nervous system
October 2015
LisdexamfetamineElvanse®ADHD in children and young adults

Central Nervous System
May 2018
LithiumMania, bipolar disorder and recurrent depression
Central Nervous System
May 2013
LofepramineDepressive illnessCentral Nervous SystemMarch 2015
LoprazolamInsomnia (short term use)
Central Nervous System
May 2013
Lorazepam injectionShort term use in anxiety and insomnia
Central Nervous System
May 2013
Lorazepam tabletsShort term use in anxiety and insomnia
Central Nervous System
May 2013
LormetazepamInsomnia (short term use)
Central Nervous System
May 2013
Low Molecular Weight HeparinsEnoxaparin® Dalteparin® Tinzaparin® Various indications
Cardiovascular SystemFebruary 2016
Loxapine inhalationSchizophrenia or bipolar disorder (NICE TA286 — terminated appraisal)
Central Nervous SystemJune 2013
LubiprostoneAmitiza®
Treating chronic idiopathic constipation (NICE TA318)
Gastro-intestinal System
September 2014
LurasidoneLatuda ®Treatment of schizophrenia in adults aged 18 and over

Central Nervous System
March 2014
Lutein and AntioxidantsAge Related Macular Degeneration
Blood and Nutrition
November 2017
MacrogolLaxido ®
Constipation in adults
Gastro-intestinal System
November 2016
Magnesium aspartate dehydrateMagnaspartate ®
Treatment and prevention of magnesium deficiency
Nutrition and Blood
October 2015
Mannitol Dry Powder for inhalationCystic Fibrosis (NICE TA266)
Respiratory System
July 2014
MelatoninNew initiation of melatonin in children with ADHD
Central Nervous system
September 2017
MelatoninChildren with ADHD already established on melatonin
Central Nervous system
September 2017
MelatoninAdults with ADHD (new initiation and patients already established on treatment)
Central Nervous system
September 2017
MelatoninChildren and adults with learning disabilities (LD) and neurodevelopmental disorders
Central Nervous system
July 2018
Melatonin M/R TabletsSlenyto®Treatment of insomnia in children and adolescents aged 2–18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.Central nervous systemApril 2019
MelatoninCircadin®Insomnia in those over 55 (short term use only)
Central Nervous System
May 2013
MemantineAlzheimer’s Disease (NICE TA217)
Central Nervous System
March 2015
Mepolizumab Nucala ®
Mepolizumab for treating severe refractory eosinophilic asthma (NICE TA431)
Respiratory system
February 2017
MeprobamateShort term use in anxiety
Central Nervous System
May 2013
Mercaptamine (cysteamine) eye dropsOcular symptoms of cystinosis
Eye
October 2014
MercaptamineCystagon®
Nephropathic cystinosis
Nutrition and Blood
October 2014
MercaptopurineUlcerative colitis and Crohn’s ONLY; only for inflammatory bowel diseases when patients are unable to tolerate azathioprine.
Gastro-intestinal System
May 2013
MesalazineUlcerative colitis
Gastro-intestinal System
October 2014
MetforminReduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with implied Glucose Tolerance and/or increased HbA1C who are:
‑at high risk for developing overt type 2 diabetes mellitus and still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3–6 month
Endocrine System
December 2017
MetforminTreatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control
Endocrine System
February 2018
MethadoneOpioid Dependence (NICE TA114)Central Nervous System
February 2015
Methotrexate subcutaneous injection penRheumatoid ArthritisMusculoskeletal and Joint Diseases
October 2014
Methotrexate (2.5mg tablets)Rheumatic diseases
Musculoskeletal and joint disease
May 2013
Methotrexate subcutaneous injection penSevere psoriasis
Skin
May 2016
Methotrexate subcutaneous injection penSevere active juvenile idiopathic arthritis
Musculoskeletal system
May 2016
Methotrexate subcutaneous injection penSevere psoriatic arthritis
Musculoskeletal system
May 2016
Methotrexate subcutaneous injection penSevere Eczema, Lichen Planus, Felty’s syndrome (unlicensed)
Skin, Musculoskeletal system
May 2016
Methotrexate subcutaneous injection penCrohn’s disease
Gastro-intestinal system
October 2014
MethylnaltrexoneOpioid induced bowel dysfunction in palliative care (NICE TA 277)
Gastro-intestinal System
May 2013
MethylphenidateADHD in children, adolescents and adults (NICE TA98)
Central Nervous System
May 2013
Methylprednisolone (injection)Acute Gout (as per LMMG Guidelines)
Endocrine system
January 2016
MetoclopramideNausea associated with acute migraine
Central Nervous SystemMay 2016
MianserinDepressive illness
Central Nervous System
May 2013
MidazolamEpistatus®
Status epilepticus
Nervous system
January 2018
MidazolamBuccolam®Status epilepticus
Central Nervous System
October 2014
MidodrineBramox ®Postural hypotensionCardiovascular SystemOctober 2015
MifepristoneMifegyne®
Termination of pregnancy
Genito-urinary systemOctober 2014
MinocyclineSusceptible infectionsInfectionJuly 2019
MirabegronBetmiga®
Symptoms of overactive bladder (NICE TA290)
Genito-urinary systemFebruary 2015
MirtazapineDepressive illnessCentral Nervous SystemMarch 2015
MoclobemideDepressive illness, social phobia
Central Nervous System
May 2013
ModafinilProvigil®Narcolepsy
Central Nervous System
October 2014
MorphinePainCentral Nervous System
January 2016
Multi-vitaminsPKU
Blood and Nutrition
July 2018
Mycophenolate MofetilComplex pain syndrome
Central Nervous system
April 2016
Mycophenolate MofetilOff label indications as defined in the LMMG Shared Care GuidelinesVariousJuly 2017
Mycophenolate MofetilCellcept® and non branded
Immunosuppresive therapy for kidney transplant in children and young people (NICE TA482)
Immune system and Malignant Disease
November 2017
Mycophenolate MofetilCellcept® and non branded
Immunosuppresive therapy for kidney transplant in adults (NICE TA481)
Immune system and Malignant Disease
November 2017
Naftidrofuryl oxalateTreatment of intermittent claudication in people with peripheral arterial disease (NICE TA223)
Cardiovascular SystemJuly 2014
NalmefeneSelincro ®Alcohol dependence (NICE TA325)
Central Nervous System
December 2014
NaloxegolConstipation in adults
Gastro-intestinal System
November 2016
NaloxegolOpioid-induced constipation (NICE TA345)
Gastro-intestinal System
September 2015
NaltrexoneOpioid Dependence (NICE TA115)
Central Nervous System
February 2015
Naltrexone/BupropionMysimba®
Managing overweight and obesity (NICE TA494)
Nervous system
January 2018
NaproxenAcute Gout (as per LMMG Guidelines)
Musculoskeletal system
January 2016
NaproxenPainMusculoskeletal system
January 2016
NatalizumabSevere relapsing remitting MS (NICE TA127)
Malignant disease and immunosuppression
May 2013
Nicotine Replacement TherapySmoking cessation
Nervous system
July 2018
NimodipineNimotop®Prevention and treatment of ischaemia following subarachnoid haemorrhage
Cardiovascular SystemOctober 2014
NintedanibOfev®
Treating idiopathic pulmonary fibrosis (NICE TA379)
Malignant Disease and immunosuppression
February 2016
NitrazepamInsomnia (short term use)
Central Nervous System
May 2013
NortriptylineNeuropathic pain
Central Nervous System
November 2016
NortriptylineDepressive illness
Central Nervous System
May 2013
Obeticholic acid Ocaliva ®
Treating primary biliary cholangitis (NICE TA443)
Gastro-intestinal system
May 2017
Ocrelizumab Ocrevus®Treating primary progressive multiple sclerosis (NICE TA585)Endocrine systemJuly 19
OcrelizumabOcrevus®
treating relapsing–remitting multiple sclerosis
Immune system and Malignant Disease
September 2018
OcriplasminJETREA®
Vitreomacular traction (NICE TA297)

Eye
November 2013
Olanzapine depot injectionSchizophrenia
Central Nervous System
May 2013
Olanzapine injectionRapid tranquilization
Central Nervous System
May 2013
OlanzapineTreatment and prophylaxis of schizophrenia
Central Nervous System
May 2013
OlodaterolStriverdi®
COPD
Respiratory system
November 2017
Omega‑3 fatty acid compoundsPrimary and secondary prevention of cardiovascular diseaseCardiovascular SystemApril 2013
OmalizumabXolair®Chronic spontaneous urticaria (NICE TA339)
Respiratory SystemJuly 2015
OmalizumabXolair®Treatment of severe persistent allergic asthma — review of TA133 & 210 (NICE TA 278)Respiratory System
May 2013
Ombitasvir / Paritaprevir / Ritonavir (Viekiraz®)Viekiraz®
With or without dasabuvir for treating chronic hepatitis C (NICE TA365)
Infections
December 2015
OpicaponeParkinson’s disease – adjunctive
therapy in adults with end-of-dose
motor fluctuations who cannot be
stabilised on preparations of
levodopa/DOPA decarboxylase
inhibitors.
Central Nervous System
November 2016
OpicaponeOngentys ®Parkinson’s disease – adjunctive therapy in adults with end-of-dose motor fluctuations who cannot be stabilised on preparations of levodopa/DOPA decarboxylase inhibitorsCentral Nervous System
November 2016
OseltamivirInfluenza treatment & prophylaxis (NICE TA158 & 168)
Infections
May 2013
OspemifeneSenshio®
Vulvovaginal or vaginal atrophy in postmenopausal women
Genito-urinary system
June 2018
OxazepamAnxiety (short term use)
Central Nervous System
May 2013
OxcarbazepineTrileptal® Treatment of epilepsy
Central Nervous System
September 2013
OxycodonePainCentral Nervous System
January 2016
Oxycodone/Naloxone (Targinact®)Targinact® Chronic pain

Central Nervous system
September 2017
Oxycodone/Naloxone (Targinact®)Targinact®Restless Legs SyndromeCentral Nervous system
December 2015
Paliperidone palmitate prolonged release suspension for injectionXeplion®Maintenance treatment of schizophrenia in adult patients
Central Nervous System
January 2016
Paliperidone (oral)SchizophreniaCentral Nervous SystemFebruary 2018
PalivizumabSynagis®
Respiratory syncytial virus in infants
Infections
October 2014
Pamidronate disodiumPagets Disease
Endocrine SystemOctober 2014
Pamidronate disodiumHypercalceamia of maligancy & Osteolytic lesions and bone pain in bone metastasesEndocrine SystemOctober 2014
ParacetamolPainCentral Nervous System
January 2016
Paracetamol/Tramadol (combination productCentral Nervous system
November 2017
Paravit-CF®Paravit-CF®
Dietary management of patients with cystic fibrosisBlood and NutritionJune 2018
ParoxetinePremature ejaculationGenito-urinary systemJanuary 2015
ParoxetineDepressive illness, post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, social phobia, generalised anxiety disorder
Central Nervous System
May 2013
Patiromer sorbitex calciumVeltassa®
Treatment of hyperkalaemia in adults
Blood and Nutrition
December 2017
PegaptanibAge-related macular degeneration (NICE TA155)
Eye
May 2013
Peginterferon Alfa-2a (Pegasys®)Pegasys®Hepatitis C (children and young people) (NICE TA300)Malignant disease and immunosuppression
December 2013
Peginterferon Alfa-2aPegasys®
Hepatitis B (NICE TA96) and Hepatitis C (NICE TA200)

Malignant Disease and Immunosuppression
November 2013
Peginterferon Alfa-2b (ViraferonPeg®)ViraferonPeg®Hepatitis C (children and young people) (NICE TA300)Malignant disease and immunosuppression
December 2013
Peginterferon Alfa-2bViraferonPeg®
Hepatitis C (NICE TA200)
Malignant Disease and Immunosuppression
November 2013
Peginterferon alfaTreatment of mild chronic hepatitis C (NICE TA106)
Malignant disease and immunosuppression
July 2014
Pelvic Floor TonerAll indicationsOctober 2014
PenicillamineRheumatic diseases
Infections
May 2013
Pentosan polysulfate sodiumElmiron®Bladder pain syndrome (interstitial cystitis)Genito-urinary systemNovember 2018
PentoxifyllinePeripheral vascular disease (NICE TA223)
Cardiovascular SystemMay 2013
PerampanelFycompa® Partial-onset seizures with or without secondary generalised seizures
Central Nervous System
February 2015
PericyazineSchizophrenia and other psychoses, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour
Central Nervous System
May 2013
Perindopril arginineHeart failure, hypertension, diabetic nephropathy and prophylaxis of cardiovascular events
Cardiovascular System
November 2017
PerphenazineSchizophrenia and other psychoses, mania, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour
Central Nervous System
May 2013
Pharmalgen®Pharmalgen®
Treatment of bee and wasp venom allergy (NICE TA246)
Respiratory System
July 2014
PhenelzineDepressive illness
Central Nervous System
May 2013
Phenoxybenzamine hydrochloride (capsules)Hypertensive episodes in phaeochromocytoma
Cardiovascular SystemOctober 2014
PimecrolimusPsoriasisSkinMay 2017
PimecrolimusTopical treatment for atopic eczema (NICE TA 82)
SkinMay 2014
PimozideSchizophrenia, monosymptomatic hypochondriacal psychosis, paranoid psychosis
Central Nervous System
May 2013
PioglitazoneType 2 diabetes
Endocrine System
February 2018
PirenzepineHypersalivation Unlicensed
Central Nervous system
March 2015
PirfenidoneEsbriet®
Treating idiopathic pulmonary fibrosis (NICE TA504)
Respiratory SystemMarch 2018
PitolisantWakix®
Treatment of narcolepsy with or without cataplexy in adults.
Central Nervous system
April 2017
PramipexoleRestless Legs Syndrome (as per LMMG Guidelines)
Central Nervous system
December 2015
PrasteroneIntrarosa®
Vulvovaginal or vaginal atrophy in postmenopausal women having moderate to severe symptoms
Genito-urinary system
June 2018
Prasugrelwith percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) (NICE TA317)
Cardiovascular SystemSeptember 2014
PrednisoloneGiant Cell ArteritisCentral Nervous SystemMay 2016
PrednisoloneCluster Headache
Central Nervous SystemMay 2016
PrednisoloneAcute Gout (as per LMMG Guidelines)
Endocrine SystemJanuary 2016
PregabalinLyrica ®Neuropathic pain (as per LMMG Guidelines)
Central Nervous system
December 2015
PregabalinRestless Legs Syndrome (off-licence as per LMMG Guidelines)
Central Nervous system
December 2015
PregabalinGeneralised anxiety disorder

Central Nervous System
May 2013
Prochlorperazine (tablets, injection, suppositories)Schizophrenia and other psychoses, mania, short term management of severe anxiety
Central Nervous System
May 2013
Procyclidine tabletsDrug induced extrapyramidal side effectsCentral Nervous System
July 2015
Promazine tabletsShort-term management of psychomotor agitation, agitation and restlessness in the elderly
Central Nervous System
May 2013
Promethazine injectionRapid tranquillisation
Central Nervous System
July 2015
Promethazine tabletsInsomnia (short term use)Central Nervous System
July 2015
Propranolol Modified ReleaseMigraine prophylaxis
Central Nervous SystemMay 2016
PropranololAnxietyCentral Nervous System
March 2015
PrucaloprideTreatment of chronic constipation in women (NICE TA211) and
Use in men: Prucalopride for the treatment of chronic constipation in men (LMMG recommendation)
Gastro-intestinal System
updated Nov 2016
PyrazinamideZinamide®
Tuberculosis in combination with other drugs
Infections
October 2014
Quetiapine xl tabletsSchizophrenia, manic episodes associated with bipolar disorder, major depressive episodes in bipolar disorder, preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, adjunct in major depressive disorder
Central Nervous System
May 2013
QuetiapineSchizophrenia, manic episodes associated with bipolar disorder, major depressive episodes in bipolar disorder, preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment.
Central Nervous System
May 2013
RaloxifeneSecondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA161)
Endocrine System
March 2015
RaloxifenePrimary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA160)Endocrine SystemMay 2013
RanibizumabMacular Oedema — retinal vein occlusion (NICE TA283)
Eye
June 2013
RanibizumabLucentis®
Choroidal neovascularisation (pathological myopia) (NICE TA298)
EyeDecember 2013
RanibizumabDiabetic Macular Oedema (NICE TA274)
Eye
May 2013
RanibizumabAge-related macular degeneration (NICE TA155)

Eye
May 2013
RanolazineAs adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies
Cardiovascular SystemMay 2013
RasagilineAzilect®MS (unlicensed)Central Nervous System
October 2014
RasagilineAzilect®Parkinson’s disease
Central Nervous System
October 2014
RasburicaseFasturtec®
Prophylaxis and treatment of acute hyperuricaemia
Musculoskeletal and joint diseases
October 2014
ReboxetineDepressive illness
Central Nervous System
May 2013
Renavit ®Renavit ®
Patients on haemodialysis
Nutrition and Blood
February 2015
ReslizumabCinqaero®
Treating severe eosinophilic asthma in adults (NICE TA479)

Respiratory systemNovember 2017
RetigabineAdjunctive treatment of partial onset seizures in epilepsy (NICE TA 232)
Central Nervous System
July 2014
RibavirinHepatitis C (NICE TA75, 106, 200)
Infections
November 2013
Rifampicin/Isoniazid/Pyrazinamide (Rifater®)Rifater®
Tuberculosis
Infections
October 2014
Rifampicin/Isoniazid (Rifanah®)Rifanah®
Tuberculosis
Infections
October 2014
Rifampicin (oral)Non-TB, Licensed indications
Infections
March 2015
Rifampicin (oral)Tuberculosis
Infections
October 2014
RifaximinTargaxan®
Preventing episodes of overt hepatic encephalopathy (NICE TA337)Infections
April 2015
RiluzoleAmyotrophic Lateral Sclerosis form of Motor Neurone Disease (NICE TA20)
Central Nervous System
July 2013
Risedronate sodiumOsteoporosis (NICE TA464)
Endocrine System
September 2017
Risperidone (Depot)SchizophreniaCentral Nervous System
May 2013
RisperidoneAcute and chronic psychoses, mania; short-term treatment of persistent aggression in patients with moderate to severe Alzheimer’s dementia unreponsive to non-pharmacological interventions and where there is a risk of harm to self or others; short-term treatment of persistent aggression in conduct disorder
Central Nervous System
May 2013
RituximabANCA Positive Vasculitis (NICE TA308)Malignant disease and immunosuppression
April 2014
RituximabLMMG RA Biologic Pathway (1st line if patient has had cancer within the last 5 years, malignant melanoma at any point, moderate CHF, ILD)
Musculoskeletal and joint disease
October 2013
RituximabRelapsing steroid sensitive nephrotic syndrome in adults
Immune system and Malignant Disease
July 2018
RituximabMembranous glomerulonephritis
Immune system and Malignant Disease
July 2018
RituximabAutoimmune haemolytic anaemia
Immune system and Malignant Disease
September 2018
RituximabIdiopathic thrombocytopenia purpura
Immune system and Malignant Disease
September 2018
RituximabRheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA195) and (LMMG RA Biologic Pathway)Musculoskeletal and joint disease
updated April 2017
RivaroxabanXarelto®Pulmonary embolism and recurrent venous thromboembolism
(NICE TA287)
Cardiovascular SystemJuly 2013
RivaroxabanXarelto®Prevention of stroke and systemic embolism in people with atrial fibrillation (NICE TA256)
Cardiovascular SystemJuly 2014
RivaroxabanXarelto®Treatment of deep vein thrombosis and prevention of recurrent DVT and pulmonary embolism (NICE TA261)
Cardiovascular SystemJuly 2014
RivaroxabanXarelto®Preventing adverse outcomes after acute management of acute coronary syndrome (NICE TA335)Cardiovascular SystemApril 2015
Rivaroxaban 10mg tabletsXarelto®
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and extended prevention of recurrent DVT and PE in adults

Cardiovascular System
June 2018
Rivaroxaban with aspirinPrevention of cardiac events in patients with coronary (CAD) or peripheral artery Disease (PAD)
Cardiovascular SystemOctober 2018
RivaroxabanXarelto®Prevention of venous thromboembolism after total hip or total knee replacement in adults (NICE TA170)
Cardiovascular SystemMay 2013
RivastigmineAlzheimer’s Disease (NICE TA 217)
Central Nervous System
March 2015
RoflumilastDaxas®
Treating chronic obstructive pulmonary disease (NICE TA461)
Respiratory System
September 2017
RomiplostimThrombocytopenic purpura in adults (NICE TA221)
Nutrition and Blood
May 2013
RopiniroleRestless Legs Syndrome (as per LMMG Guidelines)
Central Nervous system
December 2015
RopiniroleParkinsons disease
Central Nervous System
May 2013
RotigotineRestless Legs Syndrome (as per LMMG Guidelines)
Central Nervous system
December 2015
RotigotineNeupro®Parkinsons Disease
Central Nervous System
November 2013
Rubefacients (excluding topical NSAIDs)N/AMusculoskeletal system
December 2017
RufinamideInovelon®Adjunct treatment of seizures in Lennox-Gastaut syndrome
Central Nervous System
October 2014
RuxolitinibPolycythaemia vera (NICE TA356 — terminated appraisal)
Nutrition and Blood
October 2015
RuxolitinibJakavi®
Treating disease-related splenomegaly or symptoms in adults with myelofibrosis (NICE TA386)
Malignant disease and immunosuppression
April 2016
Sacubitril valsartanEntresto®Treating symptomatic chronic heart failure with reduced ejection fraction (NICE TA388)Cardiovascular SystemMay 2016
SafinamideXadago®Treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of levodopa (L‑dopa) alone or in combination with other PD medicinal products in mid to late stage fluctuating patients
Central Nervous System
December 2016
SarilumabKevzara®
Moderate to severe rheumatoid arthritis (NICE TA485)
Musculoskeletal system
November 2017
SecobarbitalSevere intractable insomnia only in patients already taking barbiturates
Central Nervous System
May 2013
SecukinumabCosentyx ®
Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (NICE TA407)
Musculoskeletal system
October 2016
SecukinumabCosentyx ® Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)Musculoskeletal systemJune 2017
SecukinumabCosentyx®
Palmoplantar psoriasis
SkinOctober 2017
SecukinumabModerate to Severe Plaque Psoriasis (NICE TA350)SkinSeptember 2015
SemaglutideOzempic ®
Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; or in addition to other medicinal products for the treatment of diabetes.Endocrine system
September 2018
Valproic acid (as semisodium valproate)Depakote®Manic episodes associated with bipolar disorder
Central Nervous System
May 2013
SennaConstipation in children
Gastro-intestinal System
November 2016
SertindoleSchizophrenia (not first line)
Central Nervous System
May 2013
SertralinePremature ejaculationGenito-urinary systemJanuary 2015
SevelamerHyperphosphataemia in patients on haemodialysis or peritoneal dialysis
Nutrition and Blood
October 2014
SildenafilRevatio®
Digital Ulceration
Genito-urinary system
September 2017
SildenafilErectile dysfunction
Genito-urinary systemOctober 2015
SildenafilRevatio®Pulmonary hypertensionCardiovascular SystemMay 2013
Silk GarmentsDermasilk®, Dreamskin® and Skinnies SilkTM
Adjunct to normal treatment for severe eczema and allergic skin conditions
SkinFebruary 2015
SimeprevirIn combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (NICE TA331)Infections
March 2015
SitagliptinJanuvia®
Type 2 diabetes
Endocrine System
February 2018
Sodium aurothimalateMyocrisin®
Rheumatoid arthritis
Musculoskeletal and joint diseases
October 2014
Sodium hyaluronate and Triamcinolone hexacetonideOsteoarthritis
Malignant Disease and ImmunosuppressionSeptember 2015
Sodium hyaluronate/Sodium chondroitin sulphate bladder instillationPain due to interstitial cystitis
Genito-urinary systemOctober 2014
Sodium oxybateXyrem®Narcolepsy with cataplexy
Central Nervous System
April 2016
Sodium ValproateUnlicensed as a mood stabiliser
Central Nervous System
May 2013
SofosbuvirTreatment of adults with chronic hepatitis C (NICE TA330)
Infections
March 2015
Sofosbuvir-velpatasvir-voxilaprevirVosevi®
Chronic hepatitis C (NICE TA507)
Infection
March 2018
Sofosbuvir–velpatasvirEpclusa ®
Sofosbuvir–velpatasvir for treating chronic hepatitis C (NICE TA430)
Infections
February 2017
Solifenacin/Tamsulosin (Vesomni®)Vesomni®
Treatment of Storage Symptoms associated with Benign Prostatic Hyperplasia
Genito-urinary systemJune 2014
SomatropinAdult growth hormone deficiency (NICE TA64) & Growth failure in children (NICE TA188)
Endocrine SystemMay 2013
SpironolactoneAcne Vulgaris
 Skin
January 2015
StiripentolDiacomit®Adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet syndrome) in combination with clobazam and valproate (under expert supervision)Central nervous systemJuly 19
StreptomycinAll indications
Infections
October 2014
Strontium RanelatePrimary and secondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA160 & 161)
Endocrine SystemMay 2014
SulfasalazineCrohn’s disease
Gastro-intestinal SystemOctober 2014
SulfasalazineRheumatoid arthritis
Musculoskeletal & Joint DiseasesOctober 2014
SulfasalazineSero-negative spondyloarthropathy including psoriatic arthritis & psoriasis (unlicensed)
Musculoskeletal system
May 2016
SulfasalazineUlcerative colitisGastro-intestinal SystemOctober 2014
Sumatriptan injectionCluster Headache
Central Nervous SystemMay 2016
TacalcitolPsoriasisSkinMay 2017
Tacrolimus Adoport® Capexion® Modigraf® Prograf® Tacni® Vivadex®
Immunosuppresive therapy for kidney transplant in children and young people (NICE TA482)
Immune system and Malignant Disease
November 2017
TacrolimusAdoport® Capexion® Modigraf® Prograf® Tacni® Vivadex®
Immunosuppresive therapy for kidney transplant in adults (NICE TA481)Immune system and Malignant Disease
November 2017
Tacrolimus (topical)Topical treatment for atopic dermatitis (NICE TA82)
SkinMay 2013
TacrolimusPsoriasisSkinMay 2017
TadalafilBenign Prostatic Hyperplasia (NICE TA273 — terminated appraisal)
Genito-urinary systemMay 2013
Tadalafil dailyCialis ®
Erectile Dysfunction — when supplied through Specialist Sexual Health ServicesGenito-urinary systemMarch 2016
Tadalafil dailyCialis ®
Erectile Dysfunction — when supplied through Primary CareGenito-urinary systemMarch 2016
Tadalafil dailyCialis®
Erectile Dysfunction Post Prostatectomy
Genito-urinary system
April 2016
Tadalafil (on demand)Cialis®
Erectile dysfunction

Genito-urinary systemOctober 2015
TadalafilAdcirca®Pulmonary hypertensionCardiovascular SystemMay 2013
Tapentadol modified releasePalexia® SR Chronic severe pain in adults
Central Nervous System
September 2013
Tapentadol modified releasePalexia ® SR
Pain in the non-palliative care setting
Central Nervous system
September 2016
TaurineTaurine deficiency in CF liver disease
Nutrition and Blood
November 2013
TelaprevirTreatment of genotype 1 chronic hepatitis C (NICE TA252)
Infections
July 2014
TemazepamInsomnia (short term use)
Central Nervous System
July 2015
Tenofovir DisoproxilTreatment of chronic hepatitis B (NICE TA173)
Infections
July 2014
TeriflunomideMultiple sclerosis — relapsing (NICE TA303)
Central Nervous System
February 2014
TeriparatideSecondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA161)
Endocrine System
May 2013
TestosteroneTestim ®Female sexual dysfunction following post oophorectomy or primary ovarian failure
Endocrine System
October 2014
TestosteroneMale hypogonadism, Androgen deficiency

Endocrine System
May 2013
TicagrelorBrilique® Prevention of atherothrombotic events after myocardial infarction in adults. (NICE TA420)Cardiovascular SystemJanuary 2017
TicagrelorBrilique®Acute Coronary Syndromes (NICE TA236)
Cardiovascular SystemOctober 2013
TildrakizumabModerate to severe Plaque PsoriasisSkinMay 2019
Tiotropium HandiHaler® 18mcg inhalation powderSpiriva ®
COPDRespiratory System
March 2014
Tiotropium Respimat® 2.5mcg solution for inhalationAsthma
Respiratory System
October 2014
Tiotropium Respimat® 2.5mcg solution for inhalationSpiriva ®
COPDRespiratory SystemMarch 2015
Tiotropium/olodaterol (Spiolto® Respimat®)Spiolto® Respimat®
COPD
Respiratory system
December 2015
Tobramycin (Dry Powder for Inhalation)Tobi® Podhaler
Cystic fibrosis (pseudomonas lung infection) (NICE TA 276)
Infections
October 2013
Tobramycin nebuleswhen inhaled for Cystic fibrosis
Infections
October 2014
TocilizumabRoActemra®Systemic Juvenile Idiopathic Arthritis (NICE TA 238)Musculoskeletal and joint diseaseMay 2013
TocilizumabRoActemra®
Treating giant cell arteritis (NICE TA518)
Musculoskeletal system
May 2018
TocilizumabRoActemra ®
Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Musculoskeletal and joint diseases
June 2015
TocilizumabRoActemra®Juvenile idiopathic arthritis in children and young people (NICE TA373)
Musculoskeletal system
January 2016
TocilizumabRoActemra®
Rheumatoid arthritis, 1st line biologic (NICE TA375) and (LMMG RA Biologic Pathway)
Musculoskeletal system
February 2016
TocilizumabRoActemra®LMMG RA Biologic Pathway (Subcutaneous at all levels where IV is used)
Musculoskeletal and joint diseases
September 2014
TocilizumabRoActemra®
Rheumatoid arthritis, 2nd and 3rd line biologic (NICE TA247) and (LMMG RA Biologic Pathway)
Musculoskeletal and joint disease
updated February 2016
TofacitinibXeljanz®Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA543)SkinNovember 2018
TofacitinibXeljanz®Tofacitinib for moderately to severely active ulcerative colitis (NICE TA547)Gastro-intestinal systemDecember 2018
TofacitinibXeljanz®

Moderate to severe rheumatoid arthritis (NICE TA480)
Musculoskeletal system
November 2017
TolcaponeTasmar®Parkinson’s disease
Central Nervous System
October 2014
TolvaptanJinarc®
Autosomal dominant polycystic kidney disease (NICE TA358)
Endocrine System
November 2015
TopiramateMigraine prophylaxis
Central Nervous SystemMay 2016
Trans-Anal Irrigation SystemsPeristeen®, Qufora®, IryPump®
Chronic Constipation or Chronic Faecal Incontinence
Gastro-intestinal system
April 2016
Trans-Anal Irrigation SystemsPeristeen®, Qufora®, IryPump®
Neurogenic Bowel Dysfunction
Gastro-intestinal system
April 2016
TranylcypromineDepressive illness
Central Nervous System
May 2013
Travel Vaccines (Cholera, Diphtheria/Tetanus/Polio, Hepatitis A, Typhoid)N/AVaccinesDecember 2017
Travel Vaccines (Hepatitis B, Japanese Encephalitits, Meningitis ACWY, Yellow Fever, Tick-borne encephalitis, Rabies, BCG)N/AVaccinesDecember 2017
TrazodoneDepressive illness
Central Nervous System
May 2013
Triamcinolone acetonide (injection)Acute Gout (as per LMMG Guidelines)
Endocrine SystemJanuary 2016
TriclofosInsomnia (short term use)
Central Nervous System
May 2013
TrifluoperazineSchizophrenia and other psychoses, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour, severe anxiety
Central Nervous System
May 2013
TrihexyphenidylDrug induced extrapyramidal side effectsCentral Nervous System
July 2015
TrimipramineDepressive illness
Central Nervous System
May 2013
Tryptophan (L‑Tryptophan)Hospital specialist initiation only for long term severe and disabling depressive illness, after trial of standard antidepressant treatment and as an adjunct to other antidepressant medication
Central Nervous System
May 2013
Ubidecarenone (Co-enzyme Q10)Mitochondrial disorders
Nutrition and Blood
October 2014
Ubidecarenone (Co-enzyme Q10)Except for mitochondrial disorders
Nutrition and Blood
October 2014
Ulipristal acetateEsmya ®Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive ageGenito-urinary systemSeptember 2018
Ulipristal acetateEsmya ®Pre-surgical treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive ageGenito-urinary systemSeptember 2018
UmeclidiniumIncruse® Ellipta®
COPD
Respiratory system
November 2017
Umeclidinium/VilanterolAnoro®Ellipta®
COPD
Respiratory system
November 2017
UstekinumabTreatment of active psoriatic arthritis — rapid review of TA 313 (NICE TA340) Musculoskeletal and joint diseases
July 2015
UstekinumabStelara®
Ulcerative Colitis
Gastro-intestinal system
May 2016
UstekinumabStelara®
Moderately to severely active Crohn’s disease after previous treatment (NICE TA456)
Gastro-intestinal system
September 2017
UstekinumabStelara®
Treating plaque psoriasis in children and young people (NICE TA455)
Skin
September 2017
Ustekinumab (sc injection)Moderate to severe plaque psoriasis (NICE TA180)
Skin
May 2013
ValganciclovirCytomegalovirus retinitis in AIDS patients, prevention of cytomegalovirus disease following solid organ transplantation from a cytomegalovirus-positive donor
Infections
May 2013
VardenafilLevitra®
Erectile dysfunction

Genito-urinary systemOctober 2015
VareniclineSmoking cessation (NICE TA123)
Central Nervous System
July 2014
Varicella-zoster (shingles) vaccineZostavax®Immunisation against herpes zoster
Vaccines September 2013
VedolizumabEntyvio®
First, second and third line treatment of moderately to severely active Crohn’s disease after prior therapy (NICE TA352)Gastro-intestinal SystemMay 2016
VedolizumabEntyvio®First, second and third line treatment of moderately to severely active ulcerative colitis (NICE TA342)Gastro-intestinal System
May 2016
VedolizumabEntyvio®Prevention of recurrence of ulcerative colitis following surgeryGastro-intestinal systemMay 2016
VedolizumabEntyvio®
Use in high risk patients for prevention of recurrence or upon recurrence of Crohn’s Disease following surgery.

Gastro-intestinal system
May 2016
Venlafaxine tablets, xl capsulesDepressive illness, generalised anxiety disorder (XL formulation only)
Central Nervous System
May 2013
Vitamin B12 (hydroxocobalamin)Following a sleeve gastrectomy
Nutrition and Blood
March 2017
Vitamin B12 (hydroxocobalamin)Following bariatric surgery performed privately
Nutrition and Blood
March 2017
Vitamin B12 (hydroxocobalamin)Following a gastric bypass
Nutrition and Blood
March 2017
Vitamin D (colecalciferol and ergocalciferol)Prophylaxis or maintenance, following treatment of deficiency and
insufficiency for symptomatic individuals that are at high or normal risk of vitamin D deficiency
Nutrition and BloodJanuary 2017

Vitamin D (colecalciferol and ergocalciferol)
Asymptomatic patients that are at high or normal risk of vitamin D deficiencyNutrition and BloodJanuary 2017
Vitamin D (colecalciferol and ergocalciferol)For the correction of deficiency and insufficiency in high-risk, symptomatic patients as a short-course treatmentNutrition and BloodJanuary 2017
Vitamins, minerals, supplements, herbal and homeopathic medicines without a Product LicenceNovember 2016
VoriconazoleVfend®
For all invasive fungal infections including those associated with transplants and aspergillosis
Infections
October 2014
VortioxetineBrintellix®Major depressive episodes (NICE TA367)
Central Nervous system
December 2015
WarfarinPrevention of stroke and systemic embolism in people with atrial fibrillation (NICE TA256)Cardiovascular SystemFebruary 2016
WarfarinTreatment of venous thromboembolismCardiovascular Systemupdated February 2016
ZaleplonShort term management of insomnia (NICE TA77)Central Nervous System
July 2015
ZanamivirInfluenza treatment & prophylaxis (NICE TA158 & 168)
Infections
May 2013
Zoledronic acidOsteoporosis (NICE TA464)
Endocrine System
September 2017
ZolpidemShort term management of insomnia (NICE TA77)Central Nervous System
October 2015
ZonisamideZonegran®EpilepsyCentral Nervous System
October 2014
ZopicloneShort term management of insomnia (NICE TA77)Central Nervous System
July 2015
Zuclopenthixol acetate injectionShort term management of acute psychosis, mania or exacerbations of chronic psychosis
Central Nervous System
May 2013
ZuclopenthixolSchizophrenia and paranoid psychosis
Central Nervous System
May 2013